Eledon Pharmaceuticals, Inc. (ELDN)

Eledon Pharmaceuticals' stock price has experienced significant volatility in the past six months. In November 2025, the stock plunged following mixed results from the Phase 2 BESTOW trial, but the company still plans to advance tegoprubart into Phase 3 development. Also in November 2025, Eledon reported preliminary positive data from the first six patients with Type 1 Diabetes treated with tegoprubart and announced a proposed $50 million underwritten public offering. In October 2025, the stock gained US$42 million in market cap. In May 2025, Eledon Pharmaceuticals was upgraded to a Zacks Rank #2 (Buy). Overall, the stock price declined by 60.71% between November 26, 2024, and November 25, 2025.

Eledon Pharmaceuticals does not currently have commercialized products or services that are subject to traditional demand seasonality. The concept of demand seasonality is not applicable at this stage of its business.

Eledon Pharmaceuticals is a clinical-stage biotechnology company that focuses on developing therapies for unmet medical needs in immunology and organ transplantation. The company's lead product candidate, tegoprubart, is in clinical trials for organ transplantation, autoimmune diseases, rare diseases, and type 1 diabetes. Eledon focuses on research and development, with revenue generation through partnerships, licensing agreements, and potential future product sales.

Eledon Pharmaceuticals is headquartered in Irvine, California, United States. The company has conducted global clinical trials for tegoprubart, including the Phase 2 BESTOW trial for kidney transplant recipients across 44 global sites.

Eledon Pharmaceuticals' brand reputation has been influenced by the outcomes of its clinical trials and subsequent stock performance. The mixed results from the Phase 2 BESTOW trial negatively impacted its reputation, while positive preliminary data from other trials and analyst upgrades contributed positively. The company's commitment to addressing unmet medical needs and its experienced leadership support its reputation.

Institutional investors hold a significant stake in Eledon Pharmaceuticals, with approximately 51% to 54.32% ownership. Hedge funds own about 26% of the company. The general public holds around 16% of the stock, while private equity firms hold approximately 6.0%. Insiders own about 12.05% of the company's stock. Major institutional owners and shareholders include BVF Inc/il, Ra Capital Management, L.p., and BlackRock, Inc. James N. Topper is noted as owning the most shares of Eledon Pharmaceuticals.